Retatrutide
10mg/vial
Triple-Action Metabolic Optimization
Retatrutide is a next-generation triple receptor agonist that simultaneously activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. It represents one of the most potent metabolic peptides in clinical and research development.
Research Metrics
HPLC verified purity
Triple receptor activation
Extended duration
Subcutaneous absorption
Mechanism of Action
Triple agonism on GLP-1R, GIPR, and GcgR produces synergistic metabolic effects: improved insulin secretion, reduced glucagon in hyperglycemic states, enhanced energy expenditure, and profound appetite suppression.
Scientific Benefits
- Weight Loss — Clinical trials show up to 24% body weight reduction over 48 weeks, superior to dual agonists.
- Blood Sugar Regulation — Enhances insulin secretion and improves insulin sensitivity for type 2 diabetes management.
- Appetite Suppression — Strongly reduces appetite via central nervous system GLP-1 receptor activation.
- Lipid Profile Improvement — Reduces triglycerides and LDL cholesterol while increasing HDL levels.
- Cardiovascular Benefits — Emerging cardioprotective effects including reduced blood pressure and inflammation markers.
- Energy Expenditure — Glucagon receptor activation increases basal metabolic rate and promotes fat oxidation.
Disclaimer & Usage Notice
GENERAL USAGE NOTICE. The products offered on this website are sold strictly for your own personal purposes. By purchasing, you acknowledge that you are assuming all risks associated with the handling and application of these products.
